Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
Poll
Featured Jobs
-
New Hampshire Physical Therapist JK1021maNET
StaffPointe, LLC - northern , NH -
Washington Nurse Practitioner
StaffPointe, LLC - Tacoma/Olympia , WA -
Colorado NP or PA
StaffPointe, LLC - southeast , CO -
Virginia Nurse Mgr Emergency Dept
StaffPointe, LLC - Fredericksburg , VA -
Texas Hospitalist
StaffPointe, LLC - south , TX
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
CT sues McKesson for allegedly inflating drug prices
The Connecticut attorney general's office is suing pharmaceutical distributor McKesson Corp., contending that it's been illegally inflating the average wholesale price of more than 400 brand-name drugs, ultimately generating millions of dollars in unnecessary costs. The suit contends that McKesson conspired with drug-price publisher First DataBank to raise average wholesale prices (the amount pharmacies and providers charge consumers and insurers for medications) from 20 to 25 percent on many drugs. At the same time, it kept the prices pharmacies and providers paid for drugs at the same level. Under these circumstances, the higher retail prices gave the pharmacies and providers a much bigger profit margin, giving them a strong incentive to work with McKesson, the state says. The suit accuses McKesson of violating Connecticut's consumer-protection laws and the federal racketeering act.
To learn more about this story:
- read this Modern Healthcare piece (reg. req.)
Related Article:
PBM study critical of role played by benefits managers
Related Stories
- Senators plan bill countering pharma detailing tactics
- Trend: States try to counter pharma drug marketing
- WA attempts prescription data mining ban
- DC passes pharma rep licensing rule
- IBM offers RFID in fight against counterfeit drugs
- Senate set to vote on Medicare, Medicaid cuts
- Comparative research studies in the past haven't always had incredible results
- Just say no: More doctors and medical centers banning drug samples
- Federal appeals court upholds NH data mining ban
- Prominent political donor gets experimental drug without permission
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





